The Additive Effect of Xalatan(0.005% Latanoprost) to Beta Adrenergic Receptor Blocker in Patients with Open Angle Glaucoma.
- Author:
Hyung Keun LEE
1
;
Gong Je SEONG
Author Information
1. The Institute of Vision Research, Department of Ophthalmology, College of Medicine, Yonsei University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Glaucoma;
IOP;
Xalatan
- MeSH:
Glaucoma;
Glaucoma, Open-Angle*;
Humans;
Iris;
Ophthalmic Solutions;
Physical Examination;
Receptors, Adrenergic*
- From:Journal of the Korean Ophthalmological Society
1998;39(1):169-176
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The effect on intraocular pressure(IOP) and side effects of adding Xalatan(0.005% Latanoprost) to beta blockers was studied in 54 eyes of 33 patients with primary open angle glaucoma that was inadequately controlled with beta blocker alone. Routine eye physical examination and IOP measurement were performed before the additive therapy. Then, the Xalatan eye drops were topically applied once a day at 5:00 PM with previously used four kind of beta blockers. IOP measured at 1 week, 1 month, 2 month, and 3 month after the combined therapy. Mean IOP was 18.6+/-3.4mmHg before combined therapy. 14.3+/-3.5mmHg after 1 week, 1 treatment, 13.5+/-3.3mmHg after 1 month, 13.1+/-2.7mmHg after 2 months and 13.1+/-2.6mmHg after 3 months the therapy. Side effects of combined therapy were conjunctival hyperemia(24.1%), eyeball pain(11.1%), tearing(7.4%), headache(5.5%) and blurred vision(3.6%). There were not any cases of iris pigment change. These results indicate that adding Xalatan in patient treated with beta blocker cause a further reduction of IOP that may prove to be clinically useful in glaucoma therapy.
